AzTrials
AzTrials

Calcific Aortic StenosisNCT04149600

Identification of Genetic Causes of Calcific Aortic Valve Disease

An observational study of Calcific Aortic Stenosis and Calcific Aortic Stenosis - Bicuspid Valve, run by Beth Israel Deaconess Medical Center at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

This study aims to identify the molecular genetic causes of the variability in development of calcific aortic valve disease in bicuspid and tricuspid aortic valves and their associated aortic dilation. Read more about this study

Who is it for?
Ages 20 years and olderHealthy volunteers can take part
What is being tested?
Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.
Type of treatment
Surgery or procedure
How many people
1,000 participants
Where
1 siteUnited States
Study dates
25 Sep 2018to 30 Jun 2027
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The investigators wish to identify the molecular genetic causes of the variability in development of calcific aortic valve disease and aortic dilation in patients with a plan to undergo elective aortic valve replacement and/or ascending aortic surgery at BIDMC.

Who may be able to join

  • Patients with a plan to undergo elective aortic valve replacement and/or ascending aortic surgery

Who cannot join

  • Age < 20 years
  • Unable/unwilling to consent
  • History of aortic valve replacement or transcatheter aortic valve replacement (TAVR)
  • History of endocarditis
  • History of rheumatic fever
  • History of chest radiotherapy
  • History of organ transplant

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

Other trials in United States

About this study

This study aims to identify the molecular genetic causes of the variability in development of calcific aortic valve disease in bicuspid and tricuspid aortic valves and their associated aortic dilation.

Being tested
Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.
Medical subject headings
Aortic Valve, Calcification of, Aortic Valve Disease, Aortic Diseases, Aortic Aneurysm, Aortic Valve Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.Procedure or surgery

    Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.

Study groups in NCT04149600
Study groupRoleWhat they receive
Bicuspid aortic valveWe wish to investigate the etiology of calcific aortic valve disease, and aortic dilation or aneurysm in patients with a bicuspid aortic valve undergoing aortic valve replacement or aortic surgery.
Receives: Procedure: Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.
Tricuspid aortic valveData and samples will be compared using a control group comprised of patients with a tricuspid aortic valve undergoing aortic surgery.
Receives: Procedure: Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Identification of expression signatures of aortic valve development and calcification in the macroscopically normal and abnormal portions of aortic valves excised during aortic valve replacement.

    We will take a portion of the aortic valve and/or aortic tissue that is routinely excised for aortic valve or aortic replacement for expression analyses and generation of fibroblast cell lines. In collaboration with the Department of Pathology, we have established methods to take sufficient "normal" and abnormal tissue while allowing formal routine pathological evaluation.

    All tissue samples for expression analysis will be transported in iced RNALater and later frozen in a -80°C research freezer, prior to next generation sequencing. We may use tissue samples to develop cell lines for indefinite use.

    Measured: 8 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Nov 2019
  2. Study start25 Sep 2018
  3. Primary completion30 Jun 2027 (estimated)
  4. Study completion30 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04149600
Sponsor's protocol ID
2018P000380
Status last verified
Jun 2026
First submitted
31 Oct 2019
Last updated
11 Jun 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in